Compare Amylx Pharmaceuticals Inc (AMLX) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Danaher Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.31 (market cap $1.98B), while Danaher Corporation trades at $199.42 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 71.2× Amylx Pharmaceuticals Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DHR | |
|---|---|---|
Market Cap | $1.98B | $140.88B |
Sector | Health | Health |
52-Week High | $18.70 | $242.05 |
52-Week Low | $7.64 | $161.91 |
Enterprise Value | $1.70B | $153.66B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Danaher (DHR) trades at $199.05, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest and profit margins have compressed from pandemic peaks. Recent business developments include the shareholder approval of the Masimo acquisition and new product launches in its SCIEX division, suggesting ongoing strategic investment.
The outlook is cautiously optimistic, supported by a dominant 'Buy' analyst consensus and a price target implying ~7% upside. Key opportunities lie in the firm's biotechnology segment strength and strategic M&A. Risks include ongoing margin pressure, integration challenges from acquisitions, and a relatively high valuation (P/E of 38.6) that demands sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
